Creating powerful nanobody treatments for COVID-19
Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization
This study is working on creating new treatments for COVID-19 using tiny antibodies from camels that can help fight the virus, making it easier to breathe and recover from the illness.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11018497 on NIH RePORTER |
What this research studies
This research focuses on developing innovative nanobody cocktails that can effectively neutralize the SARS-CoV-2 virus, which causes COVID-19. By utilizing camelid VHH antibodies, the team aims to create small, stable, and easily manufactured therapeutic agents that can be administered through various methods, including inhalation. The project employs advanced proteomic technology to identify and bioengineer highly potent nanobodies that target specific parts of the virus, potentially leading to rapid and effective treatments for COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of severe COVID-19 infection or those currently infected with the virus.
Not a fit: Patients who have already recovered from COVID-19 or those with no exposure to the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a highly effective and easily administered treatment option for COVID-19 patients.
How similar studies have performed: Previous research has shown promising results with similar nanobody approaches in neutralizing viral infections, indicating a strong potential for success in this area.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Shi, Yi — Icahn School of Medicine at Mount Sinai
- Study coordinator: Shi, Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.